epidermal growth factor receptor

Overview

The epidermal growth factor receptor (EGFR, also ErbB1/HER1) is a transmembrane receptor tyrosine kinase and the founding member of the ErbB family. Ligands such as epidermal growth factor and transforming growth factor alpha bind its extracellular region, releasing an autoinhibited conformation so the receptor can dimerize; the paired intracellular kinase domains then form an asymmetric dimer in which one activates the other, and the phosphorylated C-terminal tail recruits adaptors that launch the RAS/MAPK, PI3K/AKT and JAK/STAT cascades governing proliferation, survival and migration. Oncogenic activation follows several routes that are not interchangeable: activating kinase-domain mutations, chiefly exon 19 deletions and the L858R substitution, are characteristic of a subset of non-small cell lung cancer and confer dependence on the receptor; gene amplification with overexpression, and the truncated EGFRvIII variant, are typical of glioblastoma; and overexpression without mutation occurs in ovarian cancer, breast cancer and squamous tumors, where it predicts far less about drug response.

That distinction organizes the therapeutics. In mutation-driven lung cancer, tyrosine kinase inhibitors act on the ATP site — gefitinib and erlotinib first, then covalent agents, and now osimertinib, which was designed against the T790M gatekeeper mutation that defeated the earlier generations and has become first-line therapy; resistance to it emerges in turn through C797S, met amplification and histologic transformation. Exon 20 insertions respond poorly to all of these, which is what the amivantamab bispecific engaging EGFR and met was built for. In colorectal cancer the logic is different: the anti-EGFR antibodies cetuximab and panitumumab block ligand binding rather than the kinase, and work only where downstream KRAS and NRAS are wild type, since a mutation below the receptor makes blocking it irrelevant.

EGFR is consequently among the most frequently altered proteins in human Cancers and one of the clearest demonstrations that a target's value depends on how it is altered rather than on how much of it is present. Its inhibition also carries a predictable, mechanism-based toxicity — acneiform rash and diarrhea from blocking the same receptor in skin and gut — that tracks with response in several settings.

Recent Publications Summary

Recent publications demonstrate that epidermal growth factor receptor (EGFR) remains a central therapeutic target across multiple cancer types and therapeutic modalities. In non-small cell lung cancer, EGFR-targeted tyrosine kinase inhibitors (EGFR-TKIs) continue to be the standard approach for EGFR-mutant disease. Mefatinib, a second-generation EGFR-TKI, demonstrated significantly longer progression-free survival compared to gefitinib in EGFR-mutant NSCLC patients harboring L858R or exon 19 deletion mutations 42586967Aug. Furmonertinib at high doses showed promising intracranial efficacy with manageable safety as a first-line treatment for EGFR-mutated NSCLC with central nervous system metastases, achieving a median progression-free survival of 16.59 months and intracranial objective response rate of 95% 42379171Jun. However, baseline clinical and molecular factors have been identified that predict early progression in EGFR-TKI-treated patients, suggesting the need for improved patient stratification strategies 42536589Jul.

Drug tolerance and resistance mechanisms have emerged as significant challenges limiting EGFR-TKI efficacy. ULK1, an autophagy-related kinase, was identified as a novel therapeutic target to delay the emergence of drug-tolerant persister cells in EGFR-mutant NSCLC treated with osimertinib 42407241Jul. An oncogenic EGFR-SHC1 fusion subtype was found to confer intrinsic resistance to EGFR-TKI monotherapy through dual activation of the EGFR kinase domain and SRC-mediated phosphorylation, but dual targeted inhibition with afatinib and dasatinib induced marked tumor regression in a resistant patient 41874451Mar. Additionally, tumor cell-derived amphiregulin was identified as a mechanism driving both intrinsic and acquired resistance to KRAS inhibitors through EGFR phosphorylation, and combining KRAS inhibitors with EGFR tyrosine kinase inhibitors suppressed tumor growth 42393288Jul. These findings highlight the importance of combination strategies to overcome resistance mechanisms.

EGFR is being pursued through novel therapeutic modalities beyond conventional tyrosine kinase inhibitors. Bispecific antibodies targeting EGFR have demonstrated enhanced antitumor activity in combination with immunological approaches; an EGFRxCD16 bispecific antibody orchestrated superior natural killer cell-mediated lysis when combined with oncolytic viruses expressing GM-CSF or ICOSL 42397418Jul. gefitinib was shown to induce gefitinib-mediated endocytosis of EGFR, which can be leveraged to enhance the intracellular delivery of antibodies and nucleic acid aptamers in glioblastoma 42390764Jul. An innovative lysosome-targeting platform using LAT1-mediated chimeras (LA-LYTACs) successfully routed oncogenic EGFR and other membrane proteins to lysosomes for degradation, reducing tumor growth by more than 60% in a triple-negative breast cancer model 42545113Aug. Near-infrared photoimmunotherapy targeting EGFR was evaluated in canine mammary tumors and was found to induce immunogenic cell death 42527083Jul. EGFR-targeted gold nanoparticles delivered via convection-enhanced delivery demonstrated therapeutic potential in glioblastoma 42276782Jun.

EGFR has been integrated into multi-target drug discovery strategies across diverse cancer types and disease areas. Compounds from Tripterygium wilfordii were identified as EGFR inhibitors with anticancer activity in colorectal cancer cell lines 42595923Aug. Dual EGFR/VEGFR-2 inhibitors based on quinoxaline scaffolds exhibited potent antiproliferative activity against breast, liver, and colon cancer cell lines, with compound 12 showing IC₅₀ values comparable to erlotinib for EGFR 42054875Apr. A dual AChE/EGFR inhibitor derived from tacrine and gefitinib pharmacophores demonstrated superior blood-brain barrier permeability and neuroprotection against neuronal damage, with in vivo efficacy in reversing cognitive deficits in mice, suggesting potential in Alzheimer's disease 42107267May. EGFR inhibitors also emerged as selective therapeutic hits in low-grade serous ovarian carcinoma lacking canonical MAPK/ERK alterations 42138099May. Thiazole-based EGFR-targeted agents exhibited cytotoxic activity superior to erlotinib in lung adenocarcinoma cells, and nanoparticle formulations enhanced apoptosis induction and EGFR inhibition 42102697May. Computational studies using kinase-substrate modeling identified new EGFR phosphorylation sites and their structural determinants, providing insights into substrate specificity and pathogenic mutations 42427025Jul. Additionally, erlotinib plus bevacizumab showed clinical benefit in patients with EGFR-amplified metastatic solid tumors, including colorectal cancer and glioblastoma, with a clinical benefit rate of 44% 42298055Jun, while a spatially resolved imaging platform quantified heterogeneous EGFR antibody (panitumumab) accumulation and penetration gradients in tumors 42020148Apr.

What Changes, What Holds

1. EGFR-TKIs penetrating the blood-brain barrier provide durable intracranial control in brain-metastatic EGFR-mutant disease
NEW DIRECTION CNS penetrance as a clinical selection criterion now distinguishes EGFR-TKI generations, yet the Overview classifies their value entirely by kinase-domain selectivity and resistance mutations observed in systemically-treated disease 42379171Jun. Furmonertinib's intracranial efficacy introduces blood-brain barrier traversal as a pharmacologic property that influences treatment sequencing independently of the T790M/C797S resistance axis the established account emphasizes.

2. autophagy-mediated persistence emerges as a distinct class of acquired EGFR-TKI resistance independent of kinase mutations
NEW DIRECTION autophagy-driven persistence represents a resistance mechanism class absent from the Overview, which enumerates C797S, met amplification, and histologic transformation as routes around osimertinib 42407241Jul. ULK1 targeting offers a therapeutic angle orthogonal to kinase-domain inhibition, implying that drug tolerance in EGFR-mutant disease involves cellular programs beyond mutation-driven kinase reactivation. EGFR-SHC1 fusion likewise identifies an oncogenic variant not catalogued in the established baseline 41874451Mar, expanding the spectrum of alterations that confer resistance.

3. EGFR-targeting expands beyond kinase inhibition and antibody binding to include lysosome-directed protein degradation
NEW DIRECTION Lysosome-targeting EGFR-specific chimeras (LA-LYTACs) achieve tumor suppression through forced degradation of oncogenic receptors rather than catalytic inhibition, a mechanism entirely absent from the Overview 42545113Aug. Ligand-mediated endocytosis likewise enables EGFR-specific intracellular delivery of antibodies and therapeutic nucleic acids in glioblastoma, redirecting the classical antibody mechanism (extracellular ligand blocking) toward intracellular payload transport 42390764Jul. These modalities demonstrate EGFR-targeted drug development beyond the kinase-active and antibody-binding paradigms the established account covers.

4. Low-grade serous ovarian carcinoma lacking MAPK/ERK alterations responds to EGFR inhibition, identifying a molecular subset where EGFR predicts drug response
NEW DIRECTION Low-grade serous ovarian carcinoma lacking MAPK/ERK alterations represents a molecular subset where EGFR inhibitors emerged as selective therapeutic hits, refining the Overview's statement that EGFR expression "predicts far less about drug response" in ovarian cancer overall 42138099May. Independently, dual AChE/EGFR inhibitors achieved neuroprotection and cognitive recovery in mouse models, extending EGFR inhibition beyond cancer into neurodegenerative disease 42107267May.

Overview update candidates: Furmonertinib's intracranial efficacy in EGFR-mutant lung cancer with CNS metastases 42379171Jun.